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Abstract
Rifaximin is a semi-synthetic rifamycin derivative that is used to treat different conditions including bacterial diarrhea and
hepatic encephalopathy. Rifaximin is of particular interest because it is poorly adsorbed in the intestines and has minimal
effect on colonic microflora. We previously demonstrated that rifaximin affected epithelial cell physiology by altering
infectivity by enteric pathogens and baseline inflammation suggesting that rifaximin conferred cytoprotection against
colonization and infection. Effects of rifaximin on epithelial cells were further examined by comparing the protein
expression profile of cells pretreated with rifaximin, rifampin (control antibiotic), or media (untreated). Two-dimensional (2-
D) gel electrophoresis identified 36 protein spots that were up- or down-regulated by over 1.7-fold in rifaximin treated cells
compared to controls. 15 of these spots were down-regulated, including annexin A5, intestinal-type alkaline phosphatase,
histone H4, and histone-binding protein RbbP4. 21 spots were up-regulated, including heat shock protein (HSP) 90a and
fascin. Many of the identified proteins are associated with cell structure and cytoskeleton, transcription and translation, and
cellular metabolism. These data suggested that in addition to its antimicrobial properties, rifaximin may alter host cell
physiology that provides cytoprotective effects against bacterial pathogens.
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Introduction
Rifaximin is a semi-synthetic, poorly-absorbed (,0.4%) rifa-
mycin derivative used to treat travelers’ diarrhea due to bacterial
enteropathogens and hepatic encephalopathy (HE) [1,2,3,4,5,6].
Rifaximin also has been used for treatment of irritable bowel
syndrome, small bowel bacterial overgrowth, pouchitis, and
fulminant ulcerative colitis [2,7,8,9,10,11]. The mechanisms by
which rifaximin confers its broad range of intestinal effects remain
largely unknown [12].
Rifaximin was first approved for use in Italy in 1987. In contrast
to conventional antibiotics that have broad antimicrobial effects
dramatically altering body flora rifaximin acts primarily in the gut
[13]. We previously demonstrated that pretreatment of the HEp-2
epithelial cell line with rifaximin significantly reduced the ability of
enteroaggregative Escherichia coli (EAEC) to adhere to either the
epithelial cells or glass slides compared to untreated cells or cells
treated with the related antibiotic rifampin [14]. In addition,
epithelial cells pretreated with rifaximin had fewer detectable pro-
inflammatory cytokines present in the supernatant compared to
untreated controls. Finally, rifaximin pretreatment of HEp-2 cells
reduced Bacillus anthracis internalization into lung epithelial cells
(A549) but had no effect on Shigella sonnei internalization into
cervical epithelial (HeLa) cells. These data suggested that rifaximin
induced changes to supernatant cytokine profiles and interfered
with the cellular process utilized by some pathogens (EAEC and B.
anthracis) but not others (S. sonnei) that use a type III secretory
system to gain access to the intracellular compartment [14].
By analyzing and comparing epithelial cell protein expression
profiles following treatment with or without rifaximin (or with
control antibiotics) we were able to identify changes in the protein
expression profiles between epithelial cells in the different
treatment groups as a means of understanding how rifaximin
treatment altered HEp-2 physiology. Using 2-dimentional (2-D)
gel electrophoresis we compared the protein expression profiles of
rifaximin treated or untreated cells.
Materials and Methods
Cell Culture
HEp-2 cells (larynx-derived cell line obtained from the
American Type Culture collection [14]) were cultured in DMEM
10% fetal bovine serum media and grown to confluency as
described [14] then pretreated with rifaximin (RX), acetone
(diluent control), or rifamycin (MY) (antibiotic control), or left
untreated for 48 h. The media was removed, the cells washed 3X
with phosphate buffered saline (PBS, pH 7.4), and the cells
removed using a cell scraper. One CompleteTM Mini Protease
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inhibitor cocktail tablet (Roche Diagnostics, Indianapolis, IN)
dissolved in 500 ml was added to the cells and respective pellets
were then frozen at 280uC and shipped on dry ice to Kendrick
Labs, Inc. (Madison, WI) for analysis by 2-dimensional (2-D) gel
electrophoresis using the carrier ampholine method of isoelectric
focusing.
2-D Gel Electrophoresis
Isoelectric focusing was carried out in a glass tube with an inner
diameter 3.3 mm using 2.0% pH 3.5–10 mix 4 L ampholines for
20,000 volt-hours. One hundred ng of an IEF internal standard,
tropomyosin, was added to each sample. This protein migrated as
a doublet with a lower polypeptide spot of 33,0000 Da and pI 5.2.
A surface pH electrode was used to determine the gel pH gradient
plot for this set of ampholines. After equilibration for 10 min in
Buffer ‘O’ (10% glycerol, 50 mM dithiothreitol, 2.3% SDS, and
0.0625 M tris, pH 6.8) each tube gel was sealed to the top of a
stacking gel and overlaid with a 10% acrylamide slab gel (1.00 mm
thick). SDS slab gel electrophoresis was then carried out for 5 h at
25 mA/gel. The following proteins were used as molecular weight
standards: myosin (220,000), phosphorylase A (94,000), catalase
(60,000), actin (43,000), carbonic anhydrase (29,000), and
lysozyme (14,000). These standards appeared along the basic
edge of the silver stained 10% acrylamide slab gels. The silver-
stained gels were then dried between sheets of cellophane with the
acid edge to the left.
2-D Gel Image Analysis
To conduct comparisons between treatment groups, duplicate
gels obtained from each sample were scanned with a laser
densitometer. The scanner was checked for linearity prior to
scanning with a calibrated Neutral Density Filter Set. The images
were analyzed using Progenesis SameSpots software (version 4.0,
Nonlinear Dynamics, Durham, NC) and Progenesis PG240
software (version 2006, Nonlinear Dynamics, Durham, NC).
The general method of computerized analysis for these pairs
included image warping followed by spot finding, background
subtraction (average on boundary), matching, and quantification
in conjunction with detailed manual checking. Spot percentages
would be equal to spot integrated density above background
(volume) expressed as a percentage of total density above
background of all spots measured. Differences were defined as
fold-change of spot percentages.
Protein Digestion and Identification
Proteins up- or down-regulated by more than 1.7-fold were cut
out, washed, digested with trypsin, and analyzed by MALDI-MS
at the Protein Chemistry Core Facility at Colombia University.
Gel spots were transferred to clean tubes, hydrated with water, and
plastic coating was removed with clean forceps. Spots were
prepared for digestion by washing twice with 100 mL of 0.05 M
Tris/30% acetonitrile (pH 8.5) for 20 min. After washing, gel
spots were dried for 30 minutes in a Speed-Vac concentrator.
Gels were digested in 0.08 mg modified trypsin (sequencing
grade, Roche Molecular Biochemicals) in 13–15 mL of 0.025 M
Tris (pH 8.5) and placed on a heating block at 32uC overnight.
Peptides were extracted with 2650 mL 50% acetonitrile/2% TFA;
the combined extracts were dried and suspended in matrix
solution (10 mg/mL solution of 4-hydroxy-a-cyanocinnamic acid
in 50% acetonitrile/0.1% TFA, internal standards: angiostensin
and ACTH peptide).
Resuspended digests were spotted on sample plates and allowed
to dry. MALDI mass spectrometric analysis was done on the
digests using an Applied Biosystems Voyager DE Pro mass
spectrometer. Peptide masses were subsequently entered into
search programs utilizing the NCBI and/or GenPept databases for
protein match. Error tolerance was set at 0.5 Da for average
masses.
Results
The HEp-2 cell proteome was analyzed following cell treatment
with either rifaximin, acetone (control), rifamycin (control
antibiotic), or left untreated. A total of 1,164 spots were analyzed
using the Progenesis SameSpots software and the Progenesis
PG240 software. Representative gels analyzed for differential
expression between cells treated with rifaximin compared to
rifamycin or rifaximin compared to media alone are shown
(Figure 1A and 1B, respectively). Acetone treated cells yielded a
profile similar to that of rifamycin-treated cells or untreated cells
(data not shown). Comparison of the 2-D gel profile of HEp-2 cells
treated with rifaximin relative to the profiles defined for HEp-2
cells in each of the respective control groups identified 184
polypeptide spots differentially up- or down-regulated, however,
only 36 spots were selected for sequencing based on their
differential expression levels. Of the 36 protein spots, 26 spots
sequenced were up- or down-regulated in rifaximin-treated cells
by $2.0-fold relative to the expression profile in both control
groups. Eight protein spots were up- or down-regulated by$2.0 in
one of the two control groups analyzed. Spot 180 (intestinal-type
alkaline phosphatase) was up-regulated and spot 591 (protein
haymaker) was down-regulated, relative to both control groups by
$1.7 (Table 1). A total of 15 protein spots were down-regulated
and 21 protein spots were up-regulated, in the rifaximin treated
group compared to cells treated with rifamycin, media alone, or
acetone (data not shown) (Table 1). Spots 406 (NDRG1) and 487
(no match) (Table 1) were not significantly different in either
untreated cells or rifamycin-treated cells (relative to the expression
profile observed for rifaximin-treated cells) and are therefore not
discussed further. Spots corresponding to proteins significantly up-
or down-regulated were cut out, digested with trypsin, and
analyzed by MALDI-MS at the Protein Chemistry Core Facility at
Colombia University (Tables 2 and 3) and classified by their
respective functions (Table 4). Of the spots analyzed, 26 unique
polypeptides were positively identified, two polypeptides were
tentatively identified as tubulin beta chain and heat shock protein
HSP 90, and 11 polypeptides were unidentified. Most proteins
positively identified were associated with either cell transcription/
translation (n= 11), cell structure (n = 3), or metabolism (n= 3)
(Table 4).
Discussion
We previously demonstrated that rifaximin pre-treatment
significantly altered the attachment pattern of EAEC to HEp-2
cells and diminished the internalization of Bacilus anthracis into
A549 cells. In addition, rifaximin pretreatment diminished the
Figure 1. 2-D gel analysis. (A) HEp-2 cell 2-D profile of rifaximin (RX)-treated vs. untreated cells. Spots decreased in RX vs. untreated cells are
outlined in blue and up-regulated spots in RX vs. untreated are outlined in red. See Table 1 for spot measurements. (B) HEp-2 cell 2-D profile of RX-
treated vs. rifamycin (MY)-treated cells. Spots decreased in RX vs. MY-treated cells are outlined in blue and up-regulated spots in RX-treated vs. MY-
treated are outlined in red. See Table 1 for spot measurements.
doi:10.1371/journal.pone.0068550.g001
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number of proinflammatory cytokines detected in the supernatants
of treated cells [14]. These observations suggested that rifaximin
exerted protective effects beyond its antibiotic properties. As a
result we further examined the effects of rifaximin on HEp-2 cells
by characterizing rifaximin-mediated effects at the protein level by
2-D gel analysis of HEp-2 cells treated in the presence of rifaximin
compared to profiles observed for untreated cells or cells treated
with either rifamycin or acetone (rifaximin diluent). 2-D gel
electrophoresis analysis demonstrated that the protein expression
profile of HEp-2 epithelial cells treated with rifaximin differed
compared to the expression profile observed for HEp-2 cells
treated with acetone, rifamycin, or left untreated (Figure 1,
Table 1). Of the protein spots analyzed by MALDI-MS, 15
proteins were down-regulated in rifaximin-treated cells by .1.7-
Table 1. 2-D gel analysis profile comparing protein expression profiles between rifaximin (RX), rifamycin (MY), and untreated HEp-
2 cells.



















358 6.5 58,396 0.008 0.013 0.013 0.015 1.7 0.014 2.0 0.006
406 5.3 54,020 0.004 0.012 0.010 0.008 2.2 0.033 1.7 0.436
546 5.3 40,646 0.009 0.015 0.018 0.017 2.1 0.023 2.0 0.008
716 5.5 31,437 0.192 0.376 0.351 0.419 1.8 0.024 2.2 0.039
190 7.6 80,609 0.111 0.062 0.016 0.049 26.9 0.010 22.3 0.045
470 6.1 46,443 0.007 0.001 0.002 0.001 23.5 0.055 26.1 0.031
487 6.7 44,706 0.013 0.004 0.003 0.008 24.4 0.109 21.6 0.292
1045 6.0 16,366 0.060 0.006 0.006 0.018 29.5 0.032 23.4 0.061
1125 6.0 12,650 0.027 0.003 0.005 0.008 25.1 0.218 23.5 0.270
3 6.6 191,601 0.109 0.120 0.187 0.247 1.7 0.012 2.3 0.007
5 5.7 188,002 0.022 0.038 0.081 0.073 3.7 0.028 3.3 0.046
180 5.4 82312 0.007 0.008 0.013 0.013 1.8 0.008 1.8 0.005
312 5.2 65,196 0.087 0.110 0.144 0.176 1.7 0.007 2.0 0.000
372 5.2 57,825 0.029 0.060 0.070 0.098 2.4 0.036 3.4 0.025
630 6.5 35,676 0.007 0.006 0.022 0.014 3.3 0.127 2.2 0.043
663 5.3 33,832 0.005 0.010 0.016 0.018 3.3 0.039 3.8 0.056
714 5.7 31,602 0.005 0.003 0.009 0.012 1.7 0.001 2.3 0.000
768 7.7 28,738 0.016 0.012 0.117 0.048 7.2 0.011 2.9 0.023
800 5.4 27,641 0.003 0.005 0.011 0.012 3.3 0.030 3.7 0.287
1147 7.5 11,431 0.008 0.009 0.029 0.020 3.4 0.172 2.4 0.003
189 7.1 80,609 0.013 0.014 0.004 0.005 23.6 0.181 22.4 0.022
212 7.1 78,345 0.017 0.027 0.001 0.005 220.1 0.018 23.4 0.057
216 7.2 77,778 0.005 0.006 0.001 0.001 28.2 0.009 25.6 0.013
248 5.8 74,049 0.005 0.002 0.002 0.002 22.4 0.001 22.6 0.005
361 7.3 60,340 0.008 0.009 0.001 0.003 25.9 0.012 22.4 0.024
376 7.3 57,463 0.010 0.008 0.002 0.002 25.1 0.063 25.9 0.136
394 6.9 54,820 0.022 0.015 0.011 0.006 22.0 0.042 23.7 0.032
502 8.1 43,138 0.035 0.070 0.008 0.011 24.3 0.286 23.1 0.339
556 8.1 39,866 0.390 0.330 0.141 0.224 22.8 0.016 21.7 0.049
565 6.8 39,529 0.021 0.027 0.008 0.006 22.8 0.003 23.8 0.001
591 7.5 37,868 0.039 0.041 0.022 0.021 21.8 0.046 21.9 0.042
720 8.7 31,036 0.135 0.106 0.023 0.044 25.9 0.002 23.1 0.003
861 8.0 25,095 0.101 0.100 0.022 0.026 24.6 0.201 23.9 0.199
953 6.4 21,058 0.063 0.039 0.021 0.011 23.0 0.137 25.8 0.089
1005 8.4 17,656 0.128 0.152 0.021 0.039 26.1 0.124 23.3 0.278
1134 8.6 11,817 0.387 0.411 0.107 0.016 23.6 0.066 224.5 0.037
Reference spot numbering, pI, and MW are provided for polypeptide spots analyzed in samples RX, MY, and Media. The differences are calculated from spot
percentages (individual spot density divided by total density of all measured spots). Polypeptide spots increased in MY and Media vs. RX by a fold increase of $1.7 and
p values ,0.05 are shown in bold. Bold indicates down-regulation in samples treated with Rifaximin vs. MY or Media. Spots decreased in MY and Media vs. RX by a fold
decrease of # 21.7 and p value ,0.05 are in italics. Italics indicates up-regulated spots identified in samples treated with Rifaximin vs. MY or Media. Spot percentages
are given to indicate relative abundance. Note that the p values are for n = 2 gels/sample. A total of 1,164 spots were analyzed.
doi:10.1371/journal.pone.0068550.t001
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fold compared to the expression profile in the control groups,
including the up-regulation of annexin A5, intestinal-type alkaline
phosphatase, histone H4, and histone-binding protein RbAp48
(Table 2), and 21 spots were up-regulated by .1.7-fold including
heat shock protein HSP90a (tentative) and fascin (Table 3).
Increased annexin A5 (annexin V) expression is a marker for
apoptosis [15] and annexin V was down-regulated in rifaximin
pretreated cells. Brest et al. [16] observed that Afa/Dr expression
by diffusely adhering E. coli (Afa/Dr DAEC) decreased polymor-
phonuclear leukocyte (PMN) phagocytosis levels while inducing
apoptosis associated with increased annexin V expression [16]. In
addition, cycle inhibiting factor (Cif)-expressing EPEC induced
delayed apoptosis in intestinal epithelial (IEC-6) cells [17]. Cif is
also expressed by enterohemorrhagic E. coli (EHEC) strains
[18,19] and Samba-Louaka et al. [17] demonstrated that increased
annexin V expression levels were associated with apoptosis after
IEC-6 cells were cultured in the presence of Cif-expressing EPEC.
Furthermore, Figueiredo et al. [20] demonstrated that enterohe-
molysin (EHly) induced apoptosis of human intestinal epithelial
cells (Caco-2 and HT-29) in association with increased annexin V
expression and Fernandez-Prada et al. [21] demonstrated that
alpha-hemolysin expressing EAEC and cytodetaching E. coli
induced oncosis in human monocyte-derived macrophages and
apoptosis in J774 murine macrophages. These data suggested that
rifaximin-mediated reduction in annexin V expression may
protect cells from bacterially-induced apoptosis.
Intestinal-type alkaline phosphatase (IAP) is an enzyme that
hydrolyzes monophosphate esters and detoxifies lipopolysaccha-
rides (LPS) and is found in areas of the small and large intestines,
both inside the lumen and inside intestinal epithelial cells [22,23].
The involvement of IAP as a mucosal defense factor in the
intestines has been widely documented, however, the exact
mechanism(s) of action remain undefined [23,24,25]. Malo et al.
[26] demonstrated that the intestinal flora of IAP knock-out (IAP-
KO) mice differed from the flora of wild-type controls (IAP-WT)
and contained lower numbers of anaerobic and aerobic bacteria
recoverable from stools. Furthermore, IAP-KO mice supplement-
ed with IAP after antibiotic treatment restored healthy gut
microbiota and prevented the growth of pathogenic Salmonella
typhimurium [26]. In a separate study, Tuin et al. [27] demonstrated
that IAP was decreased in patients with inflammatory bowel
disease, a disease sometimes treated with rifaximin. Interestingly in
our study, IAP expression was down-regulated in cells pretreated
with rifaximin suggesting that IAP may not be involved in
rifaximin-mediated cytoprotection. This may also be the case for
histone H4 that was down-regulated following rifaximin treat-
ment. Some members of this protein family possess bactericidal
properties, for example, a histone H4-derived peptide (H486–100)
possessed Gram-negative (E. coli, Pseudomonas aeruginosa) and Gram-
positive (Staphylococcus aureus, Bacillus subtilis) bactericidal properties
[28] similar to other histones H1 [29,30], H2A [31,32], H2B [33],
H3, and H4 [34]. However, rifaximin-mediated down-regulation
of histone-binding protein rbbp4 (RbAp48) (a WD40 protein
family member [35] with various functions, including mediating
chromatin metabolism and assembly, Ras signaling, and cytoskel-
etal reorganization) has also been shown to bind human histone
H4. This is significant since increased RbAp48 expression was
associated with increased K-Ras activity resulting in cytoskeletal
disruption, decreased cell size, reduced cellular protrusions, and a
higher nuclear:cytoplasmic ratio [36]. Nicolas et al. [37] reported
that RbAp48 may be associated with decreased transcriptional
expression of E2-F genes during the G1 cell phase, indicating one
mechanism whereby RbAp48 may indirectly modulate mamma-
lian cell proliferation. Rifaximin-mediated reduction of RbAp48
further suggested that cytoprotection was likely due do modifica-
tions to the expression levels of proteins associated with the
Table 2. Identification of down-regulated polypeptides.
Spot # Protein








358 Tubulin Beta chain (P07437) 12 (44) 2.80E+04 76 5.50E-04
pre-mRNA processing factor 19 (Q9UMS4) 10 (42) 8.22E+04 60 2.00E-02
406 Protein NDRG1 (Q92597) 17 (50) 5.74E+08 93 1.00E-05
546 40S ribosomal protein SA (P08865) 9 (32) 2.29E+02 58 3.60E-02
716 Annexin A5 (P08758) 24 (63) 1.06E+10 166 5.10E-13
3 Carbamoyl-phosphate synthase (P31327) 19 (17) 4.63E+11 35 5.80E+00
5 Hypoxia up-regulated protein 1 (Q9Y4L1) 16 (18) 6.90E+05 84 8.80E-05
180 Intestinal-type alkaline phosphatase (P09923) 19 (46) 3.46E+08 117 4.00E-08
312 Protein disulfide isomerase (P07237) 19 (52) 5.43E+06 186 5.10E-15
372 Histone-binding protein RbbP4 (Q09028) 16 (58) 1.17E+04 186 5.10E-15
630 Tentative: Tubulin beta chain (P07437) 7 (26) 3.43E+02 nm nm
663 Deoxyribonuclease-1 (bovine) (likely
contaminate from bovine serum media) (P00639)
6 (27) 1.49E+05 66 1.50E-02
714 No Match nm nm nm nm
768 Guanine nucleotide-binding protein
subunit beta-2-like-1 (P63244)
17 (66) 6.15E+08 159 2.50E-12
800 Syntaxin-6 (O43752) 8 (52) 6.57E+11 79 2.70E-04
No match
1147 Histone H4 (P62805) 3 (29) 1.62E+02 32 1.30E+01
No match
doi:10.1371/journal.pone.0068550.t002
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cytoskeleton and cellular integrity. This observation is further
supported by the observation that fascin, an organizational protein
that bundles actin in cells [38] and highly expressed in colorectal
adenocarcinomas and in patients with inflammatory bowel disease
[3,38] was up-regulated following rifaximin treatment.
Heat shock protein HSP90a is one of the cytoprotective heat
shock proteins produced in response to cellular stresses or
environmental changes [39]. In this study, HSP90a was tentatively
identified and up-regulated in cells pretreated with rifaximin and
heat-shock proteins have also been shown to be modulators of
apoptosis [40]. Specifically, HSP90a was shown to potentially
induce or inhibit apoptosis via two distinct methods [40]. One
mechanism involved prevention of apoptosome formation and
subsequent caspase-9 formation [40] as a result of HSP90a
binding to Apaf-1 [41,42,43]; and the second by preventing
apoptosis via HSP90a interaction with NF-kB [40], RIP-1 kinase,
and Akt [44,45]. Zheng et al. [46] demonstrated that neutrophil
apoptosis following exposure to E. coli strain ATCC 25922 and S.
aureus was associated with increased expression of HSP60 and 70,
but not HSP90a. Macrophage ingestion of apoptotic neutrophils
increased cytokine production of TNFa and FcyRI surface
expression as a result of stimulation by HSP60 and 70 [46].
Further research would need to be done to confirm the presence
and identification of HSP90a and to determine if the up-
regulation of HSP90a in this study contributed to the ability of
rifaximin to protect cells against bacterial invasion or attachment.
There is a relatively wide variation among the functions of the
identified proteins (Table 4), suggesting that rifaximin may alter
cell physiology in various ways, some of which may alter the ability
of EAEC to adhere to epithelial cell surfaces and other changes
that may confer protection by preventing pathogen-induced
cytoskeletal changes resulting in the prevention of a variety of
gastrointestinal diseases. Many of the proteins identified primarily
function in controlling cell structure and the cytoskeleton,
transcription and translation, and cellular metabolism. It is
possible that rifaximin-induced alterations to the protein expres-
sion profiles are responsible for the amelioration of some of the
symptoms attributed to travelers’ diarrhea and other gastrointes-
tinal diseases.
By characterizing the protein expression profiles of cells
pretreated with rifaximin different uses for rifaximin can be
developed. This knowledge will also provide insight into the
mechanisms by which rifaximin may protect the gut against
infectious agents and how it may prevent or diminish symptoms of
disease mediated unrelated to enteric pathogens as exemplified by
hepatic encephalopathy, irritable bowel syndrome and inflamma-
tory bowel disease where this drug appears to have effects.
Author Contributions
Conceived and designed the experiments: ELB. Performed the experi-
ments: ELB CS MAG. Analyzed the data: ELB CS EM MAG HLD.
Table 3. Identification of up-regulated polypeptides.
Spot # Protein








190 Far upstream element-binding protein 1 (Q96AE4) 17 (33) 6.15E+09 90 1.80E-05
Tentative: heat shock protein HSP 90 alpha (P07900) 10 (25) 1.02E+05 nm nm
470 No match nm nm nm nm
487 No match nm nm nm nm
1045 No match nm nm nm nm
1125 No match nm nm nm nm
189 Bifunctional 39-phosphoadenosine
59-phosphosulfate synthase 1 (O43252)
19 (40) 8.06E+09 83 9.30E-05
212 Phenylalanyl-tRNA synthetase beta chain (Q9NSD9) 15 (33) 1.07E+07 90 1.80E-05
216 Phenylalanyl-tRNA synthetase beta chain (Q9NSD9) 13 (25) 6.03E+05 52 1.40E-01
248 No match; poor spectrum nm nm nm nm
361 Tubulin alpha 1B chain (P68363) 10 (29) 6.20E+05 69 2.70E-03
376 WD40 repeat-containing protein SMU1 (Q2TAY7) 13 (39) 3.52E+06 107 4.00E-07
annexin A11 (P50995) 9 (21) 1.41E+04 44 8.60E-01
394 Tubulin alpha 1B chain (P68363) 14 (47) 1.44E+08 88 3.20E-05
Fascin (Q16658) 12 (38) 3.58E+06 65 7.00E-03
502 Phosphoglycerate kinase 1 (P00558) 8 (25) 9.93E+02 46 5.60E-01
556 Heterogeneous nuclear ribonucleoprotein
C1/C2 (P07910)
6 (30) 3.05E+02 55 6.60E-02
565 Poly(rc)-binding protein 2 (Q15366) 13 (60) 3.45E+06 132 1.30E-09
591 Protein Haymaker (O96008) 10 (54) 7.61E+03 89 2.40E-05
720 No match nm nm nm nm
861 3-hydroxyacyl-CoA dehydrogenase type 2 (Q99714) 7 (38) 3.79E+04 54 9.00E-02
953 40S ribosomal protein S7 (P62081) 7 (42) 2.89E+02 68 2.90E-03
1005 No match nm nm nm nm
1134 No match nm nm nm nm
doi:10.1371/journal.pone.0068550.t003
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Contributed reagents/materials/analysis tools: ELB. Co-wrote the manu-
script: ELB CS EM MAG HLD.
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